4-[[[4-[[(1,1-二甲基乙氧基)羰基]氨基]-1-甲基-1H-吡咯-2-基]羰基]氨基]-1-甲基-1H-吡咯-2-羧酸 | 126092-98-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 4-[[[4-[[(1,1-二甲基乙氧基)羰基]氨基]-1-甲基-1H-吡咯-2-基]羰基]氨基]-1-甲基-1H-吡咯-2-羧酸
• 中文别名: 4-[(4-N-Boc-1-甲基-1H-吡咯-2-羰基)-氨基)]-1-甲基-1H-吡咯-2-羧酸
• 英文名称: 4-<<<4-<<(tert-butoxy)carbonyl>amino>-1-methylpyrrol-2-yl>carbonyl>amino>1-methylpyrrole-2-carboxylic acid
• 英文别名: 4-<<<4-<<(tert-butyloxy)carbonyl>amino>-1-methyl-pyrrol-2-yl>carbonyl>amino>-1-methyl-pyrrole-2-carboxylic acid；4-[(4-tert-butoxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)amino]-1-methyl-1H-pyrrole-2-carboxylic acid；4-[({4-[(tert-butoxycarbonyl)amino]-1-methyl-1H-pyrrol-2-yl}carbonyl)amino]-1-methyl-1H-pyrrole-2-carboxylic acid；4-[(4-tert-butyloxycarbonylamino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-1-methyl-1H-pyrrole-2-carboxylic acid；4-(4-((tert-Butoxycarbonyl)amino)-1-methyl-1H-pyrrole-2-carboxamido)-1-methyl-1H-pyrrole-2-carboxylic acid；1-methyl-4-[[1-methyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrole-2-carbonyl]amino]pyrrole-2-carboxylic acid
• CAS: 126092-98-6
• 化学式: C₁₇H₂₂N₄O₅
• 分子量: 362.385
• InChiKey: UKRBNYGJOCAJEL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  115
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  4-[[[4-[[(1,1-二甲基乙氧基)羰基]氨基]-1-甲基-1H-吡咯-2-基]羰基]氨基]-1-甲基-1H-吡咯-2-羧酸 在 盐酸 、 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.5h， 生成 4-{[4-({4-[(4-Amino-1-methyl-1H-pyrrole-2-carbonyl)-amino]-1-methyl-1H-pyrrole-2-carbonyl}-amino)-1-methyl-1H-pyrrole-2-carbonyl]-amino}-1-methyl-1H-pyrrole-2-carboxylic acid methyl ester
  参考文献：
  名称：

  Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine−Poly(N-methylpyrrole) Conjugates

  摘要：

  A novel series of methyl ester-terminated C8-linked pyrrolobenzodiazepine (PBD)-poly(N-methylpyrrole) conjugates (50a-f) has been synthesized and their DNA interaction evaluated by thermal denaturation, DNA footprinting, and in vitro transcription stop assays. The synergistic effect of attaching a PBD unit to a polypyrrole fragment is illustrated by the large increase in DNA binding affinity (up to 50-fold) compared to the individual PBD and pyrrole components. 50a-f were found to bind mainly to identical DNA sequences but with apparent binding site widths increasing with molecular length and the majority of sites conforming to the consensus motif 5'-XGXW(z) (z = 3 +/- 1; W = A or T; X = any base but preferably a purine). They also provided robust sequence-selective blockade of transcription at sites corresponding approximately to their DNA footprints. 50a-f were shown to have good cellular/ nuclear penetration properties, and a degree of correlation between cytotoxicity and DNA-binding affinity was observed.

  DOI：

  10.1021/jm051199z
• 作为产物：
  描述：

  1-甲基吡咯-2-羧酸甲酯 在 Ni-Raney 4-二甲氨基吡啶 、 sodium hydroxide 、 氢气 、 硝酸 、 乙酸酐 、 N,N'-二环己基碳二亚胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 98.0h， 生成 4-[[[4-[[(1,1-二甲基乙氧基)羰基]氨基]-1-甲基-1H-吡咯-2-基]羰基]氨基]-1-甲基-1H-吡咯-2-羧酸
  参考文献：
  名称：

  设计，合成，DNA结合和一系列DNA小沟结合插层药物的生物活性。

  摘要：

  合成了一组假肽，天然抗肿瘤剂双歧霉素或netropsin与苯胺基r啶发色团（与合成的抗白血病药物氨茶碱有关）的分子组合。确定并讨论了它们的DNA结合特性，并讨论了它们的结构差异以及与观察到的碱基依赖性结合。结合数据与模型一致，在模型中the啶核占据一个插入位点，而netropsin或distamycin残基位于DNA小沟中。报道了针对鼠细胞系的细胞抑制活性和细胞毒性活性，以及​​对DNA合成的抑制作用的显着差异。

  DOI：

  10.1002/jps.2600781106

文献信息

• [EN] DNA-TARGETED BENZOTRIAZINE 1,4-DIOXIDES AND THEIR USE IN CANCER THERAPY<br/>[FR] 1,4-DIOXIDES DE BENZOTRIAZINE CIBLEES SUR ADN ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
  申请人：AUCKLAND UNISERVICES LTD

  公开号：WO2004026846A1

  公开（公告）日：2004-04-01

  The present invention relates to DNA-targeted 1,2,4-benzotriazine- 1,4-dioxides and related analogues, to their preparation, and to their use as hypoxia-selective drugs and radiosensitizers for cancer therapy, both alone or in combination with radiation and/or other anticancer drugs.

  本发明涉及以DNA为靶标的1,2,4-苯并三氮唑-1,4-二氧化物及相关类似物，其制备方法，以及它们作为针对缺氧选择性药物和放射增敏剂在癌症治疗中的应用，无论是单独使用还是与放射线和/或其他抗癌药物结合使用。
• Synthesis of DNA-Sequence-Selective Hairpin Polyamide Platinum Complexes
  作者：Robin I. Taleb、David Jaramillo、Nial J. Wheate、Janice R. Aldrich-Wright

  DOI：10.1002/chem.200601486

  日期：2007.4.5

  DNA-sequence-selective hairpin polyamide platinum(II) complexes, containing pyrrole and imidazole heterocyclic rings, have been synthesised by different methods. A six-ring complex, selective for (A/T)GGG(A/T) DNA sequences, was made by using solid-phase synthesis, whilst an eight-ring complex, selective for (A/T)CCTG(A/T) DNA sequences, was made by utilising standard wet chemistry. Solid-phase synthesis resulted

  已通过不同方法合成了两种含有吡咯和咪唑杂环的DNA序列选择性发夹式聚酰胺铂（II）复合物。通过固相合成制备了对（A / T）GGG（A / T）DNA序列具有选择性的六环复合物，而对（A / T）CCTG（A / T）具有选择性的八环复合物DNA序列是通过使用标准的湿化学法制得的。固相合成比湿法合成具有更高的收率，更少的纯化且更有效。因此，这是进行进一步工作的首选方法。金属配合物通过（1）H和（195）Pt NMR光谱法和ESI质谱法表征。这两种化合物为合成包含多个发夹和/或铂基的更复杂分子提供了基础。
• [EN] BENZODIAZEPINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZODIAZÉPINE
  申请人：IMMUNOGEN INC

  公开号：WO2019133652A1

  公开（公告）日：2019-07-04

  The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formulae (I), (II) and (III). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

  该发明涉及具有抗增殖活性的新型苯二氮卓衍生物，更具体地涉及具有公式（I）、（II）和（III）的新型苯二氮卓化合物。该发明还提供了与细胞结合剂连接的苯二氮卓化合物的结合物。此外，该发明还提供了使用该发明的化合物或结合物抑制异常细胞生长或治疗哺乳动物增殖性疾病的有效组合物和方法。
• [EN] C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] DIMERES DE C8,C8' 5-OXO-1,2,3, 11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE LIES PAR DES LIEURS D'AMIDE D'ACIDE 1-H-PYRROLE-DICARBOXYLIQUE ET LEURS ANALOGUES OLIGOMERES AINSI QUE DES COMPOSES CONNEXES DESTINES AU TRAITEMENT DE MALADIES PROLIFERATIVES
  申请人：SPIROGEN LTD

  公开号：WO2005085250A1

  公开（公告）日：2005-09-15

  Compounds of formula (I): PBD-A-Y-X- (Het)na-L- (Het)nb-L- (Het)nc-T- (Het')nd-L- (Het')ne-L- (Het')nf-X' -Y' -A' -PBD' and salts, solvates and chemically protected forms thereof, are disclosed wherein the PBD units have the formulae (PBD) (PBD') with the bonds at the 8 position on each molecule bond to the A and A' groups respectively ; A is selected from O, S, NH or a single bond , and each Het and Het' is respectively an amino-heteroarylene-carbonyl group ; X and X' are both either NH or C (=O) -Q-C (=O) - wherein Q is a divalent group such that HY = R ; in a second aspectm the invention comprises compounds of the general formula (II) : PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X' -Y' -A' -PBD'. Wherein : PBD and PBD' are as defined above, X and X' are either NH and C(=O) respectively or C(O) and NH respectively ; the other substituents are defined in the claims. Further aspects of the present invention relate to their use in the manufacture of a medicament for the treatment of a proliferative disease.

  公式（I）的化合物：PBD-A-Y-X-（Het）na-L-（Het）nb-L-（Het）nc-T-（Het'）nd-L-（Het'）ne-L-（Het'）nf-X'-Y'-A'-PBD'及其盐、溶剂合物和化学保护形式，其中PBD单位具有化学式（PBD）（PBD'），每个分子的8位置的键分别与A和A'基团结合；A从O、S、NH或单键中选择，每个Het和Het'分别为氨基-杂芳基-羰基基团；X和X'都是NH或C（=O）-Q-C（=O）-，其中Q是二价基团，使得HY = R；在第二方面，本发明涉及一般化学式（II）的化合物：PBD-A-Y-X-(Het)ng-[L-(Het)nh] nj-X'-Y'-A'-PBD'。其中：PBD和PBD'如上所定义，X和X'分别为NH和C（=O）或C（O）和NH；其他取代基在权利要求中定义。本发明的其他方面涉及它们在制造用于治疗增殖性疾病的药物中的用途。
• Synthesis and Antitumor Activity of Duocarmycin Derivatives: A-Ring Pyrrole Compounds Bearing 5-Membered Heteroarylacryloyl Groups.
  作者：Nobuyoshi AMISHIRO、Satoru NAGAMURA、Eiji KOBAYASHI、Akihiko OKAMOTO、Katsushige GOMI、Hiromitsu SAITO

  DOI：10.1248/cpb.47.1393

  日期：——

  A series of A-ring pyrrole compounds of duocarmycin bearing 5-membered heteroarylacryloyl groups (thienylacryloyl and pyrrolylacryloyl) and heteroarylcarbonyl groups were synthesized and evaluated for in vitro anticellular activity against HeLa S3 cells and in vivo antitumor activity against murine sarcoma 180 in mice. Most of the thienylacrylates displayed in vitro anticellular activity equivalent to 4'-methoxycinnamates. Among the 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of methoxy-thienylacrylates, compound 11b, having 4'-methoxy-2'-thienylacryloyl as segment-B (Seg-B), showed remarkably potent antitumor activity and low peripheral blood toxicity in vivo, which were equal to those of 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxycinnamates, compared with the A-ring pyrrole derivatives having the trimethoxyindole skeleton in Seg-B. On the other hand, the 2'-pyrrolylacrylates having a double bond as spacer showed 102- to 103-fold stronger anticellular activity than 2'-pyrrolecarboxylates (IC50<0.3nM, 72 h-exposure). The 8-O-acetate and 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 2'-pyrrolylacrylates exhibited an antitumor effect at a lower dose compared with the 8-O-[(N-methylpiperazinyl)carbonyl] derivatives of 4'-methoxycinnamate (1j). Moreover, it was expected that the antitumor activity would be increased by the strength of the extra hydrogen bond formed between the nitrogen of the pyrrole amido group and DNA, owing to the increase of the number of N-methyl-2'-pyrrolecarboxamide units. However, 2'-pyrrolylacrylates having three N-methyl-2'-pyrrolecarboxamide units showed nearly equal antitumor activity to 2'-pyrrolylacrylates having only one N-methyl-2'-pyrrolecarboxamide unit.

  合成了一系列带有 5 元杂芳基丙烯酰基（噻吩基丙烯酰基和吡咯基丙烯酰基）和杂芳基羰基的二氢霉素 A 环吡咯化合物，并评估了这些化合物对 HeLa S3 细胞的体外抗细胞活性和对小鼠 180 型鼠肉瘤的体内抗肿瘤活性。大多数噻吩丙烯酸酯的体外抗细胞活性与 4'-甲氧基肉桂酸酯相当。在甲氧基噻吩丙烯酸酯的 8-O-[（N-甲基哌嗪基）羰基]衍生物中，以 4'-甲氧基-2'-噻吩丙烯酰基为 B 段（Seg-B）的化合物 11b 显示出显著的抗肿瘤活性和较低的体内外周血毒性、与 Seg-B 中具有三甲氧基吲哚骨架的 A 环吡咯衍生物相比，4'-甲氧基肉桂酸盐的 8-O-[（N-甲基哌嗪基）羰基]衍生物具有相同的抗肿瘤活性和低外周血毒性。另一方面，以双键为间隔的 2'- 吡咯丙烯酸酯的抗细胞活性比 2'- 吡咯羧酸酯强 102-103 倍（IC50<0.3nM，72 小时暴露）。与 4'-methoxycinnamate 的 8-O-[(N-甲基哌嗪基)羰基]衍生物相比，2'-吡咯烷丙烯酸酯的 8-O-乙酸酯和 8-O-[(N-甲基哌嗪基)羰基]衍生物的抗肿瘤作用剂量较低（1j）。此外，由于 N-甲基-2'-吡咯甲酰胺单位数量的增加，吡咯氨基氮与 DNA 之间形成的额外氢键的强度预计会提高抗肿瘤活性。不过，具有三个 N-甲基-2'-吡咯甲酰胺单元的 2'-吡咯丙烯酸酯与只有一个 N-甲基-2'-吡咯甲酰胺单元的 2'-吡咯丙烯酸酯的抗肿瘤活性几乎相同。